Drug Trial Radar · NCT04493255
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
Last checked: Nov 19, 2026Latest source record: Feb 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Sep 9, 2020
Primary completion
Oct 21, 2020
Study completion Oct 21, 2020
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- First posted
- Jul 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 35 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the pharmacokinetics (PK) and excretion of E7090 and its metabolites in healthy male participants. Also, to assess the safety and tolerability of a single dose of E7090 in healthy male participants.
Conditions
- Healthy Volunteers
Interventions
[14C]E7090Drug
\[14C\]E7090, oral capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- feu: Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in UrineTime frame: Up to Day 57
- Cumulative feu: Cumulative Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Urine From 0 to tlast HoursTime frame: Up to Day 57
- fef: Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in FecesTime frame: Up to Day 57
- Cumulative fef: Cumulative Percentage of Administered Radioactive Dose of [14C]E7090 Excreted in Feces From 0 to tlast HoursTime frame: Up to Day 57
- feu+ef: Percentage of Administered Radioactive Dose excreted of [14C]E7090 in Combined Excreta (Urine and Feces)Time frame: Up to Day 57
- Cumulative feu+ef: Cumulative Percentage of Administered Radioactive Dose excreted of [14C]E7090 in Combined Excreta (Urine and Feces) From 0 to tlast HoursTime frame: Up to Day 57
- Cmax: Maximum Observed Plasma Concentration for [14C]E7090, E7090 and its MetabolitesTime frame: Day 1: 0-672 hours post-dose
- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for [14C]E7090, E7090 and its MetabolitesTime frame: Day 1: 0-672 hours post-dose
- AUC(0-24h): Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours Postdose for [14C]E7090, E7090 and its MetabolitesTime frame: Day 1: 0-24 hours post-dose
- AUC(0-t): Area Under the Concentration- time Curve From Time 0 to Time of Last Quantifiable Concentration for [14C]E7090, E7090 and its MetabolitesTime frame: Day 1: 0-672 hours post-dose
- AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for [14C]E7090, E7090 and its MetabolitesTime frame: Day 1: 0-672 hours post-dose
- T1/2: Terminal Elimination Phase Half-life for [14C]E7090, E7090 and its MetabolitesTime frame: Day 1: 0-672 hours post-dose
- CL/F: Apparent Total Body Clearance for E7090Time frame: Day 1: 0-672 hours post-dose
- Vd/F: Apparent Volume of Distribution for E7090Time frame: Day 1: 0-672 hours post-dose
- MPR AUC(0-inf): Metabolite to Parent Ratio For AUC(0-inf) of Metabolite to E7090, Corrected for Molecular WeightsTime frame: Day 1: 0-672 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.